Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure- based virtual screening

被引:27
|
作者
Atatreh, Noor [1 ]
Ghattas, Mohammad A. [1 ]
Bardaweel, Sanaa K. [2 ]
Al Rawashdeh, Sara [1 ]
Al Sorkhy, Mohammad [1 ]
机构
[1] Al Ain Univ Sci & Technol, Dept Pharmaceut Sci, Coll Pharm, Al Ain, U Arab Emirates
[2] Univ Jordan, Dept Pharmaceut Sci, Sch Pharm, Amman 11942, Jordan
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2018年 / 12卷
关键词
protein-protein interaction; virtual screening; Mdm2; p53; anticancer; docking; pharmacophore; ELISA; P53-MDM2; INTERACTION; P53; PATHWAY; CANCER; DISCOVERY; DESIGN; POTENT;
D O I
10.2147/DDDT.S182444
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The tumor suppressor protein p53 plays an important role in preventing tumor formation and progression through its involvement in cell division control and initiation of apoptosis. Mdm2 protein controls the activity of p53 protein through working as ubiquitin E3 ligase promoting p53 degradation through the proteasome degradation pathway. Inhibitors for Mdm2-p53 interaction have restored the activity of p53 protein and induced cancer fighting properties in the cell. Purpose: The objective of this study is to use computer-aided drug discovery techniques to search for new Mdm2-p53 interaction inhibitors. Methods: A set of pharmacophoric features were created based on a standard Mdm , inhibitor and this was used to screen a commercial drug-like ligand library; then potential inhibitors were docked and ranked in a multi-step protocol using GLIDE. Top ranked ligands from docking were evaluated for their inhibition activity of Mdm2-p53 interaction using ELISA testing. Results: Several compounds showed inhibition activity at the submicromolar level, which is comparable to the standard inhibitor Nutlin-3a. Furthermore, the discovered inhibitors were evaluated for their anticancer activities against different breast cancer cell lines, and they showed an interesting inhibition pattern. Conclusion: The reported inhibitors can represent a starting point for further SAR studies in the future and can help in the discovery of new anticancer agents.
引用
收藏
页码:3741 / 3752
页数:12
相关论文
共 50 条
  • [31] NEW PLAYERS IN CANCER THERAPEUTICS: FOCUS ON INHIBITORS OF MDM2-P53 PROTEIN-PROTEIN INTERACTION
    Capdevila, J.
    Cervantes, A.
    Tabernero, J.
    DRUGS OF THE FUTURE, 2012, 37 (04) : 273 - 281
  • [32] An integrated structure- and pharmacophore-based MMP-12 virtual screening
    Ramezani, Mohammad
    Shamsara, Jamal
    MOLECULAR DIVERSITY, 2018, 22 (02) : 383 - 395
  • [33] Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction
    Neochoritis, Constantinos G.
    Atmaj, Jack
    Twarda-Clapa, Aleksandra
    Surmiak, Ewa
    Skalniak, Lukasz
    Koehler, Lisa-Maria
    Muszak, Damian
    Kurpiewska, Katarzyna
    Kalinowska-Tluscik, Justyna
    Beck, Barbara
    Holak, Tad A.
    Domling, Alexander
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 182
  • [34] MDM2-p53 Interaction inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)
    Rusiecki, Rafal
    Witkowski, Jakub
    Joanna, Jaszczewska-Adamczak
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2019, 14 (04) : 324 - 369
  • [35] Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: Molecular dynamics simulation and free energy analysis
    Chen, Jianzhong
    Wang, Jinan
    Xu, Beisi
    Zhu, Weiliang
    Li, Guohui
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2011, 30 : 46 - 53
  • [36] Identification of Aurora-A Inhibitors by Ligand and Structure-Based Virtual Screening
    Morshed, Mohammad Neaz
    MOLECULAR INFORMATICS, 2014, 33 (05) : 369 - 381
  • [37] Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search
    Chen, Si
    Li, Xiang
    Yuan, Weirong
    Zou, Yan
    Guo, Zhongwu
    Chai, Yifeng
    Lu, Wuyuan
    RSC ADVANCES, 2017, 7 (16): : 9989 - 9997
  • [38] Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors
    Espadinha, Margarida
    Lopes, Elizabeth A.
    Marques, Vanda
    Amaral, Joana D.
    dos Santos, Daniel J. V. A.
    Mori, Mattia
    Daniele, Simona
    Piccarducci, Rebecca
    Zappelli, Elisa
    Martini, Claudia
    Rodrigues, Cecilia M. P.
    Santos, Maria M. M.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 241
  • [39] Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction
    Surmiak, Ewa
    Neochoritis, Constantinos G.
    Musielak, Bogdan
    Twarda-Clapa, Aleksandra
    Kurpiewska, Katarzyna
    Dubin, Grzegorz
    Camacho, Carlos
    Holak, Tad A.
    Domling, Alexander
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 126 : 384 - 407
  • [40] MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones
    Watson, Anna F.
    Liu, Junfeng
    Bennaceur, Karim
    Drummond, Catherine J.
    Endicott, Jane A.
    Golding, Bernard T.
    Griffin, Roger J.
    Haggerty, Karen
    Lu, Xiaohong
    McDonnell, James M.
    Newell, David R.
    Noble, Martin E. M.
    Revill, Charlotte H.
    Riedinger, Christiane
    Xu, Qing
    Zhao, Yan
    Lunec, John
    Hardcastle, Ian R.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (19) : 5916 - 5919